GlobeNewswire: Addex Therapeutics Contains the last 10 of 336 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T15:52:51ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/14/2845974/0/en/Addex-to-Present-at-the-Bio-Europe-Spring-2024-Conference.html?f=22&fvtc=4&fvtv=30835Addex to Present at the Bio-Europe Spring 2024 Conference2024-03-14T06:00:00Z<![CDATA[Geneva, Switzerland, March 14, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Bio-Europe Spring 2024 conference taking place March 18 - 20, 2024 in Barcelona, Spain. Dr. Robert Lütjens, Head of Discovery – Biology, will also be attending this event.]]>https://www.globenewswire.com/news-release/2024/01/31/2820703/0/en/Addex-Enters-into-At-The-Market-ADS-Offering-Agreement-with-H-C-Wainwright-Co-LLC.html?f=22&fvtc=4&fvtv=30835Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.2024-01-31T06:00:00Z<![CDATA[Ad Hoc Announcement Pursuant to Art. 53 LR]]>https://www.globenewswire.com/news-release/2024/01/09/2805955/0/en/Addex-to-Present-at-the-Swiss-Equities-Baader-Conference.html?f=22&fvtc=4&fvtv=30835Addex to Present at the Swiss Equities Baader Conference2024-01-09T06:00:00Z<![CDATA[Geneva, Switzerland, January 9, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Dr Robert Lütjens, Head of Discovery - Biology, will present at the Swiss Equities Baader Conference being held in Bad Ragaz, Switzerland, January 10-12, 2024.]]>https://www.globenewswire.com/news-release/2024/01/05/2804455/0/en/Addex-to-Present-at-Biotech-Showcase-2024.html?f=22&fvtc=4&fvtv=30835Addex to Present at Biotech Showcase™ 20242024-01-05T06:30:00Z<![CDATA[CEO to provide update on allosteric modulator pipeline clinical and preclinical development]]>https://www.globenewswire.com/news-release/2023/12/20/2799005/0/en/Addex-Shareholders-Approve-All-Resolutions-at-Extraordinary-General-Meeting.html?f=22&fvtc=4&fvtv=30835Addex Shareholders Approve All Resolutions at Extraordinary General Meeting2023-12-20T06:00:00Z<![CDATA[Ad Hoc Announcement Pursuant to Art. 53 LR]]>https://www.globenewswire.com/news-release/2023/12/14/2795964/0/en/Addex-Creates-Treasury-Shares.html?f=22&fvtc=4&fvtv=30835Addex Creates Treasury Shares2023-12-14T06:00:00Z<![CDATA[Ad Hoc Announcement Pursuant to Art. 53 LR]]>https://www.globenewswire.com/news-release/2023/11/29/2787467/0/en/Addex-Reports-Q3-2023-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=30835Addex Reports Q3 2023 Financial Results and Provides Corporate Update2023-11-29T06:00:00Z<![CDATA[Ad Hoc Announcement Pursuant to Art. 53 LR]]>https://www.globenewswire.com/news-release/2023/11/28/2786599/0/en/Addex-Convenes-Extraordinary-General-Meeting.html?f=22&fvtc=4&fvtv=30835 Addex Convenes Extraordinary General Meeting2023-11-28T06:00:00Z<![CDATA[Ad Hoc Announcement Pursuant to Art. 53 LR]]>https://www.globenewswire.com/news-release/2023/11/23/2785106/0/en/Addex-Therapeutics-to-Release-Third-Quarter-2023-Financial-Results-and-Host-Conference-Call-on-November-29-2023.html?f=22&fvtc=4&fvtv=30835Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 20232023-11-23T06:00:00Z<![CDATA[Geneva, Switzerland, November 23, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that that it will issue its Third Quarter 2023 Financial Results on November 29, 2023. Tim Dyer, CEO , Robert Lütjens, Head of Discovery – Biology and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 GMT / 10:00 EST / 07:00 PST) the same day.]]>https://www.globenewswire.com/news-release/2023/11/14/2779698/0/en/Addex-ADX71149-Epilepsy-Phase-2-Study-Completes-Recruitment-of-Patients.html?f=22&fvtc=4&fvtv=30835Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients2023-11-14T06:00:00Z<![CDATA[Ad Hoc Announcement Pursuant to Art. 53 LR]]>